ID   USPC-ARK-6
AC   CVCL_IV77
SY   USPC ARK-6; USPC-ARK6; ARK6
DR   cancercelllines; CVCL_IV77
DR   Cosmic; 2640556
DR   Wikidata; Q54991978
RX   PubMed=19920829;
RX   PubMed=21246534;
RX   PubMed=23891627;
RX   PubMed=27894751;
CC   Population: Caucasian.
CC   Microsatellite instability: Instable (MSI-high) (Note=After >50 passages) (PubMed=27894751).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.His67Asn (c.199C>A); ClinVar=VCV000473501; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Ala1967Val (c.5900C>T); ClinVar=VCV000246263; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Asp368Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Ala832Thr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Cys1642Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Gly2076Val; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Leu2207Ile; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission).
CC   Miscellaneous: Correct age of donor (not 62 year old as indicated in PubMed=19920829) and sequence variation in POLE by personal communication of Santin, Alessandro D.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C27838; Endometrial serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 13
//
RX   PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756;
RA   El-Sahwi K.S., Bellone S., Cocco E., Cargnelutti M., Casagrande F.,
RA   Bellone M., Abu-Khalaf M., Buza N., Tavassoli F.A., Hui P.,
RA   Silasi D.-A., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S.,
RA   Santin A.D.;
RT   "In vitro activity of pertuzumab in combination with trastuzumab in
RT   uterine serous papillary adenocarcinoma.";
RL   Br. J. Cancer 102:134-143(2010).
//
RX   PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671;
RA   Varughese J., Cocco E., Bellone S., de Leon M., Bellone M.,
RA   Todeschini P., Schwartz P.E., Rutherford T.J., Pecorelli S.,
RA   Santin A.D.;
RT   "Uterine serous papillary carcinomas overexpress human
RT   trophoblast-cell-surface marker (Trop-2) and are highly sensitive to
RT   immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal
RT   antibody.";
RL   Cancer 117:3163-3172(2011).
//
RX   PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020;
RA   English D.P., Bellone S., Cocco E., Bortolomai I., Pecorelli S.,
RA   Lopez S., Silasi D.-A., Schwartz P.E., Rutherford T.J., Santin A.D.;
RT   "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications
RT   determine the sensitivity of uterine serous carcinoma cell lines to
RT   GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase
RT   (TORC1/2).";
RL   Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013).
//
RX   PubMed=27894751; DOI=10.1016/j.ygyno.2016.11.023; PMCID=PMC5183545;
RA   Bellone S., Bignotti E., Lonardi S., Ferrari F., Centritto F.,
RA   Masserdotti A., Pettinella F., Black J.D., Menderes G., Altwerger G.,
RA   Hui P., Lopez S., de Haydu C., Bonazzoli E., Predolini F.,
RA   Zammataro L., Cocco E., Ferrari F., Ravaggi A., Romani C.,
RA   Facchetti F., Sartori E., Odicino F.E., Silasi D.-A., Litkouhi B.,
RA   Ratner E., Azodi M., Schwartz P.E., Santin A.D.;
RT   "Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates
RT   with T lymphocyte infiltration and increased resistance to
RT   platinum-based chemotherapy in vitro.";
RL   Gynecol. Oncol. 144:146-152(2017).
//